CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home ItemIn Person Seminar: Win to Fight and Lose to Flight: Innate Yet Flexible Aggression Circuit , home
March 24, 2023, 11 a.m. | Dayu Lin, Ph.D., Professor, Department of Psychiatry, Grossman School of Medicine, New York University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home ItemSeminar: Signaling and Metabolic Control of Nucleotide Metabolism in Cancer , home
March 27, 2023, 11 a.m. | Eunus S. Ali, Ph.D., Postdoctoral Associate, Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University | Seminar
-
Home ItemIn Person Seminar: Quantifying Diverse Research Representation , home
March 31, 2023, 11:00 a.m. | Jonathan Jackson, Ph.D., Executive Director, Community Access, Recruitment, and Engagement (CARE) Research Center, Harvard University and Massachusetts General Hospital | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home ItemIn Person Lecture: Synaptic Injury: A Link to the Past , home
March 31, 2023, 1 p.m. | Terrance Kummer, M.D., Ph.D., Associate Professor of Neurology, Washington University School of Medicine in St. Louis | Timothy A. Johnson Medical Scholar Lecture Series
-
Home ItemSeminar: Understanding Cancer: From Development to Therapy , home
April 5, 2023, 11 a.m. | Biplab Dasgupta, M.S., Ph.D., MBA, Professor of Pediatrics, Division of Oncology, Cincinnati Children's Hospital | Seminar
-
Home ItemIn Person Seminar: Brain Dynamics and Flexible Behaviors , home
April 14, 2023, 11:00 am. | Lucina Q. Uddin, Ph.D., Professor in Residence, Department of Psychiatry and Biobehavioral Science, University of California, Los Angeles | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Addiction Recovery Research Center and Center for Health Behaviors Research